Post by Jazz Pharmaceuticals

248,932 followers

We recognize the complexities of HER2 cancers, which is why we’ve placed a strategic focus on HER2 development to help address the ongoing unmet needs faced by patients and their families.    Global Head of R&D and Chief Medical Officer Robert Iannone sat down with Fierce Pharma to discuss the evolving landscape of HER2-targeted agents in cancer care and how we’re continuing to build our HER2 platform to drive long-term impact for patients and their families. Watch the full interview to learn more: https://bit.ly/4egsZuJ

Post content

Video Content